清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

滤泡性淋巴瘤 医学 耐火材料(行星科学) 队列 卵泡期 肿瘤科 内科学 淋巴瘤 CD20 生物 天体生物学
作者
Kim Linton,Umberto Vitolo,Wojciech Jurczak,Pieternella J. Lugtenburg,Emmanuel Gyan,Anna Sureda,Jacob Haaber Christensen,Brian T. Hess,Hervé Tilly,Raúl Córdoba,David John Lewis,Craig Okada,Martin Hutchings,Michael Roost Clausen,Juan‐Manuel Sancho,Tara Cochrane,Sirpa Leppä,Martine E.D. Chamuleau,Diana Gernhardt,Işıl Altıntaş
出处
期刊:The Lancet Haematology [Elsevier BV]
卷期号:11 (8): e593-e605 被引量:41
标识
DOI:10.1016/s2352-3026(24)00166-2
摘要

Background A standard of care and optimal duration of therapy have not been established for patients with multiply relapsed or refractory follicular lymphoma. The aim of this study was to evaluate epcoritamab, a novel CD3 × CD20 bispecific antibody, in the third-line and later setting of follicular lymphoma. Methods EPCORE NHL-1 is a multicohort, single-arm, phase 1–2 trial conducted at 88 sites across 15 countries. Here, we report the primary analysis of patients with relapsed or refractory follicular lymphoma in the phase 2 part of the trial, which included the pivotal (dose expansion) cohort and the cycle 1 optimisation cohort. Eligible patients were aged 18 years or older, had relapsed or refractory CD20+ follicular lymphoma (grade 1–3A), an Eastern Cooperative Oncology Group performance status of up to 2, and had received at least two previous lines of therapy (including an anti-CD20 monoclonal antibody and an alkylating agent or lenalidomide). Patients were treated with subcutaneous epcoritamab 48 mg in 28-day cycles: weekly in cycles 1–3, biweekly in cycles 4–9, and every 4 weeks until disease progression or unacceptable toxicity. To mitigate the risk and severity of cytokine release syndrome, in the pivotal cohort, cycle 1 consisted of a step-up dosing regimen of a 0·16-mg priming dose on day 1 and a 0·80-mg intermediate dose on day 8, followed by subsequent 48-mg full doses and prophylactic prednisolone 100 mg; in the cycle 1 optimisation cohort, a second intermediate dose of 3 mg on day 15, adequate hydration, and prophylactic dexamethasone 15 mg were evaluated during cycle 1 to further reduce risk and severity of cytokine release syndrome. Primary endpoints were independently reviewed overall response rate for the pivotal cohort and the proportion of patients with grade 2 or worse and any-grade cytokine release syndrome for the cycle 1 optimisation cohort. Analyses were done in all enrolled patients who had received at least one dose of epcoritamab. This study is registered with ClinicalTrials.gov, NCT03625037, and is ongoing. Findings Between June 19, 2020, and April 21, 2023, 128 patients (median age 65 years [IQR 55–72]; 49 [38%] female and 79 [62%] male) were enrolled and treated in the pivotal cohort (median follow-up 17·4 months [IQR 9·1–20·9]). The overall response rate was 82·0% (105 of 128 patients; 95% CI 74·3–88·3), with a complete response rate of 62·5% (80 of 128; 95% CI 53·5–70·9). The most common grade 3–4 treatment-emergent adverse event was neutropenia in 32 (25%) of 128 patients. Grade 1–2 cytokine release syndrome was reported in 83 (65%) of 128 patients; grade 3 cytokine release syndrome was reported in two (2%). Immune effector cell-associated neurotoxicity syndrome was reported in eight (6%) of 128 patients (five [4%] grade 1; three [2%] grade 2). Between Oct 25, 2022, and Jan 8, 2024, 86 patients (median age 64 years [55–71]; 37 [43%] female and 49 [57%] male) were enrolled and treated in the cycle 1 optimisation cohort. The incidence of cytokine release syndrome was 49% (42 of 86 patients; eight [9%] grade 2; none of grade 3 or worse), with no reported immune effector cell-associated neurotoxicity syndrome. Interpretation Epcoritamab monotherapy showed clinically meaningful activity in patients with multiply relapsed or refractory follicular lymphoma, and had a manageable safety profile. Funding Genmab and AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
FashionBoy应助康康XY采纳,获得30
4秒前
科研通AI2S应助科研通管家采纳,获得10
6秒前
9秒前
蓝天阳光完成签到,获得积分10
16秒前
18秒前
59秒前
量子星尘发布了新的文献求助10
59秒前
科研通AI2S应助chenqi采纳,获得10
1分钟前
1分钟前
白天亮完成签到,获得积分10
1分钟前
完美世界应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
Owen应助科研通管家采纳,获得10
2分钟前
Owen应助科研通管家采纳,获得10
2分钟前
Glitter完成签到 ,获得积分10
2分钟前
00完成签到 ,获得积分10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
3分钟前
康康XY发布了新的文献求助30
3分钟前
3分钟前
3分钟前
研友_8y2G0L完成签到,获得积分10
3分钟前
mathmotive完成签到,获得积分20
4分钟前
双手外科结完成签到,获得积分10
4分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
4分钟前
梵莫发布了新的文献求助10
4分钟前
4分钟前
nojego完成签到,获得积分10
4分钟前
5分钟前
量子星尘发布了新的文献求助10
5分钟前
5分钟前
5分钟前
梵莫发布了新的文献求助10
6分钟前
深情安青应助科研通管家采纳,获得10
6分钟前
6分钟前
量子星尘发布了新的文献求助10
6分钟前
CodeCraft应助康康XY采纳,获得10
6分钟前
无一完成签到 ,获得积分0
6分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Immigrant Incorporation in East Asian Democracies 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3972811
求助须知:如何正确求助?哪些是违规求助? 3517116
关于积分的说明 11186225
捐赠科研通 3252713
什么是DOI,文献DOI怎么找? 1796589
邀请新用户注册赠送积分活动 876487
科研通“疑难数据库(出版商)”最低求助积分说明 805701